Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer Franz Blaes, MD, Markus Klotz, Hanno Huwer, MD, Uwe.

Slides:

Advertisements

Similar presentations

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Advertisements

Elizabeth A. David, MD, David T

AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma Daniel L. Albertus, BS, Christopher.

Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD

Primary non-Hodgkin’s lymphoma of the lung

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio.

E-cadherin expression associated with differentiation and prognosis in patients with non–small cell lung cancer Dage Liu, MD, Cheng-long Huang, MD, Kotaro.

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

Chun Chieh Lin, PhD, MBA, Matthew P

Joshua E. Rosen, BASc, Hari B

Clinicopathological and biological assessment of lung cancers with pleural dissemination Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Lars P. Riber, MD, PhD, Thomas D. Christensen,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi Shibuya, MD, Tetsuya.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung Cancer Katsuhiko Matsuyama, Yukio Chiba, Masato Sasaki, Hirokazu Tanaka, Ryusuke.

Prognostic Significance of the Tumor Suppressor Gene Maspin in Non–Small Cell Lung Cancer Kyoji Hirai, MD, Kiyoshi Koizumi, MD, Shuji Haraguchi, MD,

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma Masahiro Yasunaga,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X in Non-Small Cell Lung Cancer Shinjiro Mizuguchi, MD, PhD, Noritoshi Nishiyama, MD,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer Aritoshi Hattori, MD, Takeshi Matsunaga, MD, Kazuya.

Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Kenji Suzuki, MD, Hisao.

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Sex-associated differences in survival of patients undergoing resection for lung cancer Mark K Ferguson, MD, Jun Wang, MD, Philip C Hoffman, MD, Daniel.

Iwao Takanami, MD, Ken Takeuchi, MD, Masatoshi Giga, MD

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Mariano Garcı́a-Yuste, MD, José M

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Prognostic factors in clinical stage I non–small cell lung cancer

Expression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung Cancer Zhenfa Zhang, MD, Jianqun Ma, MD, Ni Li, PhD, Nan Sun, MD,

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma Masahiko Higashiyama, MD, Ken Kodama, MD, Hideoki Yokouchi,

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Pretransplant Panel Reactive Antibodies in Human Lung Transplantation: An Analysis of Over 10,000 Patients Ashish S. Shah, MD, Lois Nwakanma, MD, Christopher.

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Modern Outcome and Risk Analysis of Surgically Resected Occult N2 Non-Small Cell Lung Cancer Hyun Jin Cho, MD, Sung Ryong Kim, MD, Hyeong Ryul Kim, MD,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer Bernward Passlick, MD, Boris Kubuschok, MD,

Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker Adnan Sayar,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Joseph S Coselli, MD, Lori D Conklin, MD, Scott A LeMaire, MD

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Mark I. Block, MD The Annals of Thoracic Surgery

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer Franz Blaes, MD, Markus Klotz, Hanno Huwer, MD, Uwe Straub, MD, Gerhard Kalweit, MD, Klaus Schimrigk, MD, Hans-Joachim Schäfers, MD The Annals of Thoracic Surgery Volume 69, Issue 1, Pages 254-258 (January 2000) DOI: 10.1016/S0003-4975(99)01198-4

Fig 1 Survival of autoantibody-positive and -negative (AnAb and/or ANA) NSCLC patients shown as Kaplan-Meier plot (p = 0.0004). The Annals of Thoracic Surgery 2000 69, 254-258DOI: (10.1016/S0003-4975(99)01198-4)

Fig 2 Immunofluorescence staining of a NSCLC serum on cerebellar tissue. Axonal staining around the Purkinje cells (serum dilution 1:500, magnification ×500). The Annals of Thoracic Surgery 2000 69, 254-258DOI: (10.1016/S0003-4975(99)01198-4)

Fig 3 Western blot using cerebellar soluble protein fraction as antigens. (Lane S) Standard (Novex Mark 12); (lane 1) anti-Hu-positive NSCLC patient with a typical reactivity at 38 kDa; (lane 2) NSCLC patient with a 45-kDa reactivity and axonal staining, as shown in Figure 1; (lane 3) healthy control patient. The Annals of Thoracic Surgery 2000 69, 254-258DOI: (10.1016/S0003-4975(99)01198-4)

Fig 4 Survival functions of antineural antibody-positive and -negative NSCLC patients presented as Kaplan-Meier plots. (A) All patients (p = 0.005); (B) stage I and II (p = 0.056); (C) stage III (p = 0.026). The Annals of Thoracic Surgery 2000 69, 254-258DOI: (10.1016/S0003-4975(99)01198-4)

Fig 5 Survival functions of stage III patients grouped by ANA finding presented as Kaplan-Meier plots. Log-rank test showed a significantly better prognosis of the ANA-positive stage III patients (p = 0.0025). The Annals of Thoracic Surgery 2000 69, 254-258DOI: (10.1016/S0003-4975(99)01198-4)